Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30

The claim, and the short answer

The post names six peptides: BPC-157, TB-500, MOTS-c, KPV, semax and epitalon. These are the six that FDA's Pharmacy Compounding Advisory Committee recommended for the 503A bulks list on July 23 and 24, 2026, against the advice of FDA's own staff. The committee rejected a seventh, emideltide (DSIP). A committee vote is advice, and FDA still has to act on it.

FDA itself still has not acted. What changed is that HHS has said it will not enforce the rules against compounders who meet its conditions. Calling that a green light overstates it. The policy is not binding, it does not change any law, and HHS says it can take it back.

What HHS published

The notice was filed on October 28 and published in the Federal Register on October 30, 2026 (91 FR 68526, docket HHS-OASH-2026-0496). It is signed by the HHS Secretary. It says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, a federal facility or a licensed physician who compounds a drug from one of the six. It says HHS took this step because of the committee meetings and data on how these peptides are used, and because no approved products are available.

The policy is meant to cover the time while FDA builds the 503A bulks list through rulemaking. The notice says FDA's future rules "may propose" adding some or all of the six, depending on the evidence. That is a possibility, not a promise. HHS says it may change the policy if a safety signal or a product quality problem appears. In its own words, the policy "is not binding on HHS or the public." The notice also calls it a draft, and it took public comments for two weeks after publication.

The conditions

The policy covers each peptide only in one chemical form and only by certain routes:

• BPC-157 (acetate): injection under the skin or into muscle, by mouth, or on the skin.
• TB-500 and MOTS-c (acetate): injection under the skin or into muscle.
• Epitalon (acetate): injection under the skin or into muscle, given in intermittent courses.
• Semax (free base): in the nose only.
• KPV (acetate): on the skin or by mouth.

The raw ingredient must come from a manufacturer that is registered with FDA and follows good manufacturing practice. The certificate of analysis must name that manufacturer's site and report tests for identity, purity, strength and contaminants. Each product may contain only one of the six, so blends are not covered. The label must say "This is a compounded drug product. Not for resale." The only device that may come with the product is a syringe cleared by FDA. For tablets or other oral forms, the compounder must keep evidence that the formulation is actually absorbed in people. Compounders must report what they make, along with serious adverse events and quality problems, to FDA's MedWatch program and to their state. A prescription for a named patient is still required, and so are the other conditions of section 503A.

What did not change

• The 503A bulks list. None of the six has been added. Adding one requires a rule, published first as a proposal with a comment period.
• FDA's categories. FDA's list of nominated substances was still dated May 14, 2026 when we read it on November 4. None of the six is in Category 1, and FDA's safety-risk page still lists them among withdrawn nominations.
• Approval. None of the six is an approved drug. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality, and the notice says so.
• Emideltide. The peptide the committee rejected is not in the policy.
• Products sold outside a pharmacy. The policy covers compounding by pharmacies, federal facilities and physicians that meet its conditions. It does not cover vials sold online as "research use only".
• FDA's own pages. As of November 4, no FDA page we checked mentions the policy. The July meeting page still carries no minutes, and the page for the next meeting, which is due before the end of February 2027 to consider five more peptides, still gives no date.

What the post gets wrong

The action came from HHS, not FDA. The policy is a promise not to enforce, made on conditions and open to change, not a ruling that these peptides are allowed. It also comes with limits on form, route, sourcing and labelling that the post leaves out, and those limits decide whether a given product is covered at all. The things to watch next are whether FDA proposes a rule adding any of the six to the list and whether HHS changes the policy after the comment period.

Related on Grey Peptides